These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses. Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599 [TBL] [Abstract][Full Text] [Related]
5. Dihydropyridine agonist Bay K 8644 inhibits platelet activation by competitive antagonism of thromboxane A2-prostaglandin H2 receptor. Johnson GJ; Dunlop PC; Leis LA; From AH Circ Res; 1988 Mar; 62(3):494-505. PubMed ID: 2449295 [TBL] [Abstract][Full Text] [Related]
6. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910 [TBL] [Abstract][Full Text] [Related]
7. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets. Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950 [TBL] [Abstract][Full Text] [Related]
8. Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on platelet aggregation and thrombosis. Kondo K; Seo R; Naka M; Kitagawa T; Wakitani K; Sakata M; Kira H; Okegawa T; Kawasaki A Eur J Pharmacol; 1989 Apr; 163(2-3):253-61. PubMed ID: 2721574 [TBL] [Abstract][Full Text] [Related]
9. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953 [TBL] [Abstract][Full Text] [Related]
10. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets. Mais DE; Kochel PJ; Saussy DL; Halushka PV Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736 [TBL] [Abstract][Full Text] [Related]
11. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe. Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474 [TBL] [Abstract][Full Text] [Related]
12. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro. De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278 [TBL] [Abstract][Full Text] [Related]
13. Competitive antagonism at thromboxane receptors in human platelets. Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580 [TBL] [Abstract][Full Text] [Related]
15. Effect of thromboxane receptor antagonists on venous thrombosis in rats. Schumacher WA; Heran CL J Pharmacol Exp Ther; 1989 Mar; 248(3):1109-15. PubMed ID: 2522985 [TBL] [Abstract][Full Text] [Related]
16. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Bertele V; De Gaetano G Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787 [TBL] [Abstract][Full Text] [Related]
17. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Watts IS; Wharton KA; White BP; Lumley P Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620 [TBL] [Abstract][Full Text] [Related]
18. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors. Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist. Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268 [TBL] [Abstract][Full Text] [Related]
20. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. Yin K; Halushka PV; Yan YT; Wong PY J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]